Dr. Reddy's Laboratories Limited
RDYNYSEHealthcare● Active
$13.26
+$0.02(+0.11%)
Market Cap$11.0B
P/E Ratio—
52W High$16.17
52W Low$12.19
Dr. Reddy's Laboratories Limited (RDY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RDY · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $353.47B | $325.54B | $279.16B | $245.88B | $214.39B |
| Cost of Revenue | $166.95B | $135.11B | $115.56B | $106.54B | $100.55B |
| Gross Profit | $186.52B | $190.43B | $163.61B | $139.34B | $113.84B |
| Gross Margin %(computed) | 52.77% | 58.50% | 58.61% | 56.67% | 53.10% |
| Operating Expenses | |||||
| R&D Expenses | $25.31B | $27.38B | $22.87B | $19.38B | $17.48B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $137.65B | $118.58B | $95.88B | $82.20B | $84.36B |
| Operating Income | $48.87B | $71.84B | $67.73B | $57.14B | $29.48B |
| Operating Margin %(computed) | 13.83% | 22.07% | 24.26% | 23.24% | 13.75% |
| Interest Income | $8.28B | $2.68B | $2.28B | $1.18B | $0.96B |
| Interest Expense | $3.93B | $2.83B | $1.71B | $1.43B | $0.96B |
| Income Before Tax | $57.68B | $76.78B | $71.87B | $60.37B | $32.30B |
| Income Tax Expense | $13.00B | $19.54B | $16.19B | $15.30B | $8.73B |
| Net Income | $45.09B | $56.54B | $55.68B | $45.07B | $23.57B |
| Net Margin %(computed) | 12.76% | 17.37% | 19.95% | 18.33% | 10.99% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $53.92 | $67.85 | $66.80 | $54.29 | $28.42 |
| Wtd Avg Shares | 0.83B | 0.83B | 0.83B | 0.83B | 0.83B |
| EBITDA | $70.55B | $96.67B | $88.42B | $74.43B | $45.08B |
| EBITDA Margin %(computed) | 19.96% | 29.70% | 31.67% | 30.27% | 21.03% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · INR · B
Explore more Dr. Reddy's Laboratories Limited data
About Dr. Reddy's Laboratories Limited (RDY) Income Statement
Dr. Reddy's Laboratories Limited (RDY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, RDY reported revenue of $353.47B, gross profit of $186.52B (gross margin 52.77%), and net income of $45.09B — a net profit margin of 12.76%.
Frequently asked questions
RDY · 4 questionsDr. Reddy's Laboratories Limited (RDY) reported revenue of $353.47B for 2026, up 8.6% year-over-year.
RDY revenueRDY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08